Merck

MRK

Market cap $210B

Keytruda continues to dominate, driving 50% of revenue, with new approvals and delivery methods strengthening MRK's oncology leadership. The company's long-term outlook is also promising, with a full pipeline of new final-stage drugs, an expanding vaccine portfolio, and breakthroughs in animal health products. Despite patent and regulatory risks, MRK's low valuation, strong balance sheet, and 3.8% dividend yield make it appealing for long-term investors.

The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck & Co. Inc. (NYSE:MRK) on Wednesday announced additional data from two Phase 3 studies of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with virologically suppressed HIV-1 infection.

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the signing of a definitive agreement to acquire the chromatography business of JSR Life Sciences, a leader in contract development and manufacturing, preclinical and translational clinical research, and bioprocessing solutions. The acquisition will expand Merck's downstream processing portfolio with advanced Protein A chromatography capabilities, supporting more efficient and scalable producti.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the presentation of additional data from the Phase 3 studies of the investigational, once-daily, oral, two-drug regimen of doravirine/islatravir [DOR/ISL (100mg/0.25mg)] in adults with HIV-1 infection that was virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamidei [BIC/FTC/TAF (50 mg/200 mg/25 mg)] in trial MK-8591A-052 or antiretroviral therapy [baseline.

In the closing of the recent trading day, Merck (MRK) stood at $84.81, denoting a -1.04% move from the preceding trading day.

Turning $10,000 into $50,000 in about five years would require a compound annual growth rate (CAGR) of almost 38%. That's an extremely tough task for any corporation, but can Merck (MRK -0.41%), a leading pharmaceutical company, pull it off?

Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Merck has increased its dividend for 14 consecutive years. Its 10-year dividend growth rate of 5.4% is only decent. Merck increased its revenue from $39.5 billion in FY 2015 to $64.2 billion in FY 2024. That's a compound annual growth rate of 5.5%. Merck has a good financial position. The long-term debt/equity ratio is 0.7, while the interest coverage ratio is over 16.

A value stock is generally one that trades at a price lower than its fundamental value or what its performance suggests it should be worth.